step 1 trial semaglutide 2.4 mg weight loss nejm 2021 Once-weekly 7·2 in adults with obesity (STEP UP): a randomised, controlled, phase 3b Semaglutide Dosage for Weight Loss:

Comparative Receptor Mechanisms and Efficacy Expectations Tirzepatide activates both GIP and GLP-1 receptors, producing synergistic glucose control and robust weight loss averaging 20-22% at maximum dose in clinical trials

Always calculate your volume based on your specific concentration before selecting a syringe size

Ketosis: Ozempic can cause ketosis (a metabolic state where your body burns fat for energy instead of carbohydrates), which may cause a distinct breath odor

Providers should also assess medication adherence and GI tolerance capacity, as dual therapy demands careful monitoring during initiation and titration phases